631 related articles for article (PubMed ID: 19781577)
1. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
2. A small molecule fusion inhibitor of dengue virus.
Poh MK; Yip A; Zhang S; Priestle JP; Ma NL; Smit JM; Wilschut J; Shi PY; Wenk MR; Schul W
Antiviral Res; 2009 Dec; 84(3):260-6. PubMed ID: 19800368
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL
Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of flavivirus membrane fusion.
Stiasny K; Fritz R; Pangerl K; Heinz FX
Amino Acids; 2011 Nov; 41(5):1159-63. PubMed ID: 19882217
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein.
Kato D; Era S; Watanabe I; Arihara M; Sugiura N; Kimata K; Suzuki Y; Morita K; Hidari KI; Suzuki T
Antiviral Res; 2010 Nov; 88(2):236-43. PubMed ID: 20851716
[TBL] [Abstract][Full Text] [Related]
6. Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
Li PC; Jang J; Hsia CY; Groomes PV; Lian W; de Wispelaere M; Pitts JD; Wang J; Kwiatkowski N; Gray NS; Yang PL
ACS Infect Dis; 2019 Mar; 5(3):460-472. PubMed ID: 30608640
[TBL] [Abstract][Full Text] [Related]
7. Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.
Parkinson T; Pryde DC
Future Med Chem; 2010 Jul; 2(7):1181-203. PubMed ID: 21426163
[TBL] [Abstract][Full Text] [Related]
8. Strategies for development of Dengue virus inhibitors.
Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses.
Lee E; Pavy M; Young N; Freeman C; Lobigs M
Antiviral Res; 2006 Jan; 69(1):31-8. PubMed ID: 16309754
[TBL] [Abstract][Full Text] [Related]
10. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein.
Lee E; Weir RC; Dalgarno L
Virology; 1997 Jun; 232(2):281-90. PubMed ID: 9191841
[TBL] [Abstract][Full Text] [Related]
11. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation.
Mondotte JA; Lozach PY; Amara A; Gamarnik AV
J Virol; 2007 Jul; 81(13):7136-48. PubMed ID: 17459925
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
Aarthy M; Singh SK
Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
[TBL] [Abstract][Full Text] [Related]
13. Antiviral peptides targeting the west nile virus envelope protein.
Bai F; Town T; Pradhan D; Cox J; Ashish ; Ledizet M; Anderson JF; Flavell RA; Krueger JK; Koski RA; Fikrig E
J Virol; 2007 Feb; 81(4):2047-55. PubMed ID: 17151121
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL
ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735
[TBL] [Abstract][Full Text] [Related]
15. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs.
Pastorino B; Nougairède A; Wurtz N; Gould E; de Lamballerie X
Antiviral Res; 2010 Sep; 87(3):281-94. PubMed ID: 20452379
[TBL] [Abstract][Full Text] [Related]
16. The flavivirus polymerase as a target for drug discovery.
Malet H; Massé N; Selisko B; Romette JL; Alvarez K; Guillemot JC; Tolou H; Yap TL; Vasudevan S; Lescar J; Canard B
Antiviral Res; 2008 Oct; 80(1):23-35. PubMed ID: 18611413
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
[TBL] [Abstract][Full Text] [Related]
18. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
[TBL] [Abstract][Full Text] [Related]
19. A structural perspective of the flavivirus life cycle.
Mukhopadhyay S; Kuhn RJ; Rossmann MG
Nat Rev Microbiol; 2005 Jan; 3(1):13-22. PubMed ID: 15608696
[TBL] [Abstract][Full Text] [Related]
20. Novel binding between pre-membrane protein and claudin-1 is required for efficient dengue virus entry.
Gao F; Duan X; Lu X; Liu Y; Zheng L; Ding Z; Li J
Biochem Biophys Res Commun; 2010 Jan; 391(1):952-7. PubMed ID: 19962368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
